Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 22, 2020BloodOpen Access

CANOMAD: a neurological monoclonal gammopathy of clinical significance that benefits from B-cell–targeted therapies

View Full Paper
Ask AI
Bookmark
Share

Authors

MCMarie Le CannFBFrançoise BouhourKVKarine Viala

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Cann et al. (2020) studied this question.

synapsesocial.com/papers/6a71a09efebe604dd70a338ahttps://doi.org/10.1182/blood.2020007092
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Acute relapsing sensory neuropathy associated with IgM antibody against B‐series ganglio‐sides containing a GalNAcß1–4(Gal3–2αNeuAc8–2αNeuAc)ß1 configuration1992 · 61 citations
  2. 2Chronic ataxic neuropathies associated with anti-GD1b IgM antibodies: response to IVIg therapy2009 · 52 citations
  3. 3Improving the Assessment of Outcomes in Stroke2002 · 870 citations
  4. 4Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications2018 · 301 citations
  5. 5Sensory neuropathy associated with monoclonal immunoglobulin M to GD1b ganglioside1992 · 91 citations